IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

iOmx Therapeutics AG, based in Martinsried/Munich, Germany, has announced the appointment of Florian Schmid as the new Chief Financial Officer (CFO). Florian Schmid steps in as Marcus Irsfeld departs to explore new opportunities at the end of June.

Dr. Apollon Papadimitriou, CEO of iOmx, expressed enthusiasm for Florian's extensive background in financial strategy, international capital markets, and biotech leadership. He also thanked Marcus Irsfeld for his contributions to the company's success over the years.

Florian Schmid shared his excitement about joining iOmx, recognizing the company's progress in cancer immune biology and strong management. Florian brings over two decades of experience from previous roles at Vivoryon Therapeutics, InflaRx, and Deutsche Telekom.

Florian Schmid holds a degree in business economics from Ludwig-Maximilians-University of Munich and is both a Certified Public Accountant and Certified German Tax Advisor.